Logo

Varian to Acquire Boston Scientific's Oncology Assets for $90M

Share this

Varian to Acquire Boston Scientific's Oncology Assets for $90M

Shots:

  • Varian acquires the Boston Scientific drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products for the treatment of arteriovenous malformations and hypervascular tumors for $90M
  • The focus of the acquisition is to expand Varian’s interventional oncology portfolio and to get benefits from the acquired product’s regulatory clearances in 35+ countries globally
  • Varian plans to manufacture & distribute the products without acquiring Boston Scientific operations. The transaction is expected to close on Aug’2019

Click here to read full press release/ article | Ref: Varian | Image: Glassdoor


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions